hVIVO’s Mo Khan: “the industry is really waking up to the value of human challenge models”
Episode 1554, Jul 25, 2023, 01:08 PM
(Watch the video interview HERE)
Mo Khan, chief executive of hVIVO (HVO), talks to Vox Markets about the company’s latest contract win, a £13.1m deal to develop a human challenge model for Influenza B with an existing client, and how the approach is gathering momentum across the industry.
0:36 Details of the new £13.1m contract with an existing big pharma client to
develop a new human challenge model for influenza B.
2:25 How human challenge models are helping the industry develop highly-
targeted treatments, and enabling fast-tracked regulatory approval.
4:28 Next steps in the development of the influenza B human challenge model,
and the ability to leverage the model in future.
6:18 The challenges presented in developing influenza treatments, and how
human challenge models can help to bring flu under control.
Mo Khan, chief executive of hVIVO (HVO), talks to Vox Markets about the company’s latest contract win, a £13.1m deal to develop a human challenge model for Influenza B with an existing client, and how the approach is gathering momentum across the industry.
0:36 Details of the new £13.1m contract with an existing big pharma client to
develop a new human challenge model for influenza B.
2:25 How human challenge models are helping the industry develop highly-
targeted treatments, and enabling fast-tracked regulatory approval.
4:28 Next steps in the development of the influenza B human challenge model,
and the ability to leverage the model in future.
6:18 The challenges presented in developing influenza treatments, and how
human challenge models can help to bring flu under control.